1. Home
  2. LYFT vs IOVA Comparison

LYFT vs IOVA Comparison

Compare LYFT & IOVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Lyft Inc.

LYFT

Lyft Inc.

HOLD

Current Price

$13.30

Market Cap

5.1B

ML Signal

HOLD

Logo Iovance Biotherapeutics Inc.

IOVA

Iovance Biotherapeutics Inc.

HOLD

Current Price

$3.55

Market Cap

1.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LYFT
IOVA
Founded
2007
2007
Country
United States
United States
Employees
N/A
N/A
Industry
Business Services
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.1B
1.4B
IPO Year
2019
2008

Fundamental Metrics

Financial Performance
Metric
LYFT
IOVA
Price
$13.30
$3.55
Analyst Decision
Hold
Buy
Analyst Count
30
10
Target Price
$20.14
$9.11
AVG Volume (30 Days)
14.9M
15.3M
Earning Date
05-07-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
11250.00
14.84
EPS
6.81
N/A
Revenue
$6,316,261,000.00
N/A
Revenue This Year
$17.73
$51.55
Revenue Next Year
$12.39
$37.55
P/E Ratio
$1.86
N/A
Revenue Growth
9.16
N/A
52 Week Low
$9.66
$1.64
52 Week High
$25.54
$5.63

Technical Indicators

Market Signals
Indicator
LYFT
IOVA
Relative Strength Index (RSI) 45.39 45.90
Support Level $12.97 $2.02
Resistance Level $14.24 $4.34
Average True Range (ATR) 0.49 0.30
MACD 0.08 -0.12
Stochastic Oscillator 43.35 17.23

Price Performance

Historical Comparison
LYFT
IOVA

About LYFT Lyft Inc.

Lyft is the second-largest ride-sharing service provider in the US and Canada, connecting riders and drivers over the Lyft app. Incorporated in 2013 and public since 2019, Lyft offers a variety of rides via private vehicles, including traditional private rides, shared rides, and luxury ones. Besides ride-share, Lyft has entered the bike- and scooter-share market to bring multimodal transportation options to users.

About IOVA Iovance Biotherapeutics Inc.

Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. It operates in one segment, focusing on innovating, developing, and commercializing therapies using its autologous TIL cell therapies for patients with solid tumor cancers. Geographically, the company operates in United States and Rest of the World.

Share on Social Networks: